Public disclosures

Company insiders

Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.

Advertisement
More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSourceFollow
Thurman Alex R.

SVP & CHIEF FINANCIAL OFFICER · GLAUKOS Corp

GKOS

GLAUKOS Corp

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 49305 · SEC code covers open-market or private transactions · The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2026 with respect to options that expire on March 15, 2027. · This transaction was executed in multiple trades at prices ranging from $236.89 to $237.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. · Includes 5,230 restricted stock units that have not yet vested or been delivered to the Reporting Person.

2026-11-182026-11-20

≈ $479,846.03

2,021 shares/units

SEC 4Follow
Thurman Alex R.

SVP & CHIEF FINANCIAL OFFICER · GLAUKOS Corp

GKOS

GLAUKOS Corp

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 51326 · SEC code covers open-market or private transactions · The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2026 with respect to options that expire on March 15, 2027. · This transaction was executed in multiple trades at prices ranging from $235.28 to $235.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. · Includes 5,230 restricted stock units that have not yet vested or been delivered to the Reporting Person.

2026-11-182026-11-20

≈ $129,054.00

548 shares/units

SEC 4Follow
Thurman Alex R.

SVP & CHIEF FINANCIAL OFFICER · GLAUKOS Corp

GKOS

GLAUKOS Corp

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 51874 · SEC code covers open-market or private transactions · The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2026 with respect to options that expire on March 15, 2027. · This transaction was executed in multiple trades at prices ranging from $234.22 to $235.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. · Includes 5,230 restricted stock units that have not yet vested or been delivered to the Reporting Person.

2026-11-182026-11-20

≈ $547,037.40

2,330 shares/units

SEC 4Follow
Thurman Alex R.

SVP & CHIEF FINANCIAL OFFICER · GLAUKOS Corp

GKOS

GLAUKOS Corp

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 54204 · SEC code covers open-market or private transactions · The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2026 with respect to options that expire on March 15, 2027. · This transaction was executed in multiple trades at prices ranging from $233.21 to $234.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. · Includes 5,230 restricted stock units that have not yet vested or been delivered to the Reporting Person.

2026-11-182026-11-20

≈ $348,794.66

1,493 shares/units

SEC 4Follow
Thurman Alex R.

SVP & CHIEF FINANCIAL OFFICER · GLAUKOS Corp

GKOS

GLAUKOS Corp

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 55697 · SEC code covers open-market or private transactions · The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2026 with respect to options that expire on March 15, 2027. · This transaction was executed in multiple trades at prices ranging from $232.18 to $233.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. · Includes 5,230 restricted stock units that have not yet vested or been delivered to the Reporting Person.

2026-11-182026-11-20

≈ $746,573.85

3,209 shares/units

SEC 4Follow
Thurman Alex R.

SVP & CHIEF FINANCIAL OFFICER · GLAUKOS Corp

GKOS

GLAUKOS Corp

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 58906 · Includes 5,230 restricted stock units that have not yet vested or been delivered to the Reporting Person.

2026-11-182026-11-20

15,000 shares/units

SEC 4Follow
Mendelsohn Aaron

Director · Vivani Medical, Inc.

VANI

Vivani Medical, Inc.

Equity grant or award
Filing details

SEC transaction code A

Original filed 2026-11-19

Common Stock · Indirect ownership · See footnote · Reported balance after transaction: 997327 · The reporting person purchased 99,010 shares of the Issuer's common stock in a private sale transaction as disclosed in the Share Purchase Agreement dated as of November 15, 2026 at a price of $1.01 per share, which was the last reported sale price of the Issuers common stock on the Nasdaq on November 13, 2026 (the trading day immediately prior to November 15, 2026). The gross proceeds from this private sale transaction were $100,000.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased in the transaction set forth in this footnote. · On November 19, 2026, the reporting person filed a Form 4 which inadvertently included an incorrect transaction code due to an administrative error. This amendment is being filed to reflect the correct transaction code "A" instead of transaction code "D." · The reporting person owns 1,165,497 shares directly and/or indirectly as follows: (i) 168,170 shares of common stock owned by the reporting person, (ii) 150,930 shares in five trusts, each of which has been established for a separate grandchild of the Reporting Person, with each trust owning an aggregate of 30,186 shares of common stock, all trusts with the same terms, over which the Reporting Person has voting and dispositive authority, (iii) 846,397 shares of common stock owned by MFE, LLC over which the Reporting Person has voting and dispositive authority. The Reporting Person disclaims pecuniary interest in 20% of MFE, LLC and therefore disclaims 169,279 shares of the 846,397 shares of common stock owned by MFE, LLC, which 169,279 shares are beneficially owned by other members of the limited liability company.

2026-11-182026-11-20

99,010 shares/units

SEC 4/A

Amendment

Follow
KELLY SARA

evp, chief partner officer · STARBUCKS CORP

SBUX

STARBUCKS CORP

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 68637.7023 · Securities delivered or withheld for tax or exercise payment · Shares withheld by the issuer to satisfy tax withholding obligations upon vesting of restricted stock units; not an open market transaction.

2026-11-182026-11-20

1,099.046 shares/units

SEC 4Follow
LOUNDERMON WENDY

Chief Financial Officer · Game Your Game Inc.

GYGY

Game Your Game Inc.

Equity grant or award
Filing details

SEC transaction code A

Stock Option (Right to Buy Common Stock) · Derivative security · Direct ownership · Reported balance after transaction: 200000 · The stock option is granted under Game Your Game, Inc.'s 2026 Equity Incentive Plan, as amended from time to time. · The stock options vest 1/48th each month starting from the grant date.

2026-10-232026-11-20

200,000 shares/units

SEC 4Follow
BREWER BRADY

ceo, International · STARBUCKS CORP

SBUX

STARBUCKS CORP

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 87949.386 · Securities delivered or withheld for tax or exercise payment · Shares withheld by the issuer to satisfy tax withholding obligations upon vesting of restricted stock units; not an open market transaction.

2026-11-182026-11-20

1,761.7 shares/units

SEC 4Follow
Das Soumya

Chief Executive Officer · Director · Game Your Game Inc.

GYGY

Game Your Game Inc.

Equity grant or award
Filing details

SEC transaction code A

Stock Option (Right to Buy Common Stock) · Derivative security · Direct ownership · Reported balance after transaction: 500000 · The stock option is granted under Game Your Game, Inc.'s 2026 Equity Incentive Plan, as amended from time to time. · The stock options vest 1/48th each month starting from the grant date.

2026-10-232026-11-20

500,000 shares/units

SEC 4Follow
Reppas Tiah Norton

Chief Accounting Officer · DarkHorse Technologies Inc.

DRK

DarkHorse Technologies Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 68045 · SEC code covers open-market or private transactions

2026-11-202026-11-20

≈ $20,155.00

14,500 shares/units

SEC 4Follow
DERSE NATALIE MARIE

CFO · Gen Digital Inc.

GEN

Gen Digital Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 589250 · SEC code covers open-market or private transactions · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.4150 to $30.5250, inclusive. The reporting person undertakes to provide to Gen Digital Inc., any security holder of Gen Digital Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range reported in this footnote. · Exhibit 24 Power of Attorney

2026-11-182026-11-20

≈ $2,204,208.57

72,341 shares/units

SEC 4Follow
DUGGAN ROBERT W

Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc.

SMMT

Summit Therapeutics Inc.

Exercise or conversion
Filing details

SEC transaction code M

Stock Option (right to buy) · Derivative security · Indirect ownership · By Spouse · Reported balance after transaction: 500000 · On November 20, 2026, the Spouse of Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share. · The option was granted to the Spouse of Reporting Person on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025.

2026-11-202026-11-20

300,000 shares/units

SEC 4Follow
DUGGAN ROBERT W

Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc.

SMMT

Summit Therapeutics Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Indirect ownership · By Spouse · Reported balance after transaction: 831000 · On November 20, 2026, the Spouse of Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share. · The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

2026-11-202026-11-20

300,000 shares/units

SEC 4Follow
Brosius Mark

EVP & Chief Mfg and Supply Cha · INTUITIVE SURGICAL INC

ISRG

INTUITIVE SURGICAL INC

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 227 · SEC code covers open-market or private transactions · The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.

2026-11-202026-11-20

≈ $18,733.04

46 shares/units

SEC 4Follow
Brosius Mark

EVP & Chief Mfg and Supply Cha · INTUITIVE SURGICAL INC

ISRG

INTUITIVE SURGICAL INC

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 273 · SEC code covers open-market or private transactions · The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.

2026-11-192026-11-20

≈ $19,363.70

46 shares/units

SEC 4Follow
DelOrefice Christopher

Director · RESMED INC

RMD

RESMED INC

Equity grant or award
Filing details

SEC transaction code A

ResMed Common Stock · Direct ownership · Reported balance after transaction: 2977 · Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2027, or the annual meeting of stockholders in the year following the grant date.

2026-11-192026-11-20

554 shares/units

SEC 4Follow
Zanganeh Mahkam

Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc.

SMMT

Summit Therapeutics Inc.

Exercise or conversion
Filing details

SEC transaction code M

Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 500000 · On November 20, 2026, the Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share. · The option was granted on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025.

2026-11-202026-11-20

300,000 shares/units

SEC 4Follow
Zanganeh Mahkam

Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc.

SMMT

Summit Therapeutics Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 831000 · On November 20, 2026, the Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share.

2026-11-202026-11-20

300,000 shares/units

SEC 4Follow
Rider Michael J

Global General Counsel · RESMED INC

RMD

RESMED INC

Other transaction
Filing details

SEC transaction code F

ResMed Common Stock · Direct ownership · Reported balance after transaction: 12919 · Securities delivered or withheld for tax or exercise payment · Disposition to issuer for tax withholding on vesting of performance-based restricted stock units granted on 11/16/2023

2026-11-192026-11-20

3,084 shares/units

SEC 4Follow
Rider Michael J

Global General Counsel · RESMED INC

RMD

RESMED INC

Equity grant or award
Filing details

SEC transaction code A

ResMed Common Stock · Direct ownership · Reported balance after transaction: 16004 · Represents performance-based restricted stock units granted on November 16, 2023. The shares were earned on November 19, 2026, when the compensation and leadership development committee certified that the performance metrics were met for this portion of the grant.

2026-11-192026-11-20

5,587 shares/units

SEC 4Follow
KEENE HAROLD L

Director · 10% owner · NEW PEOPLES BANKSHARES INC

NWPP

NEW PEOPLES BANKSHARES INC

Buy
Filing details

SEC transaction code P

Common Stock · Indirect ownership · Harold Lynn Keene Trust · Reported balance after transaction: 85074 · SEC code covers open-market or private transactions

2026-11-192026-11-20

≈ $5,100.00

1,000 shares/units

SEC 4Follow
KEENE HAROLD L

Director · 10% owner · NEW PEOPLES BANKSHARES INC

NWPP

NEW PEOPLES BANKSHARES INC

Gift or transfer
Filing details

SEC transaction code W

Common Stock · Indirect ownership · H.L. Keene LLC · Reported balance after transaction: 1127567 · The inheritance of 857 shares reported herein occurred on July 29, 2020, and was not previously reported. This transaction is being reported at this time to reflect the Reporting Person's beneficial ownership accurately. · The amount reported reflects the correction of a prior clerical error that duplicated a 2,000-share transaction occurring on June 16, 2023. No disposition of securities occurred as a result of this correction.

2020-07-292026-11-20

857 shares/units

SEC 4Follow
BRIDGEWATER TIMOTHY A

Chief Executive Officer · Director · 10% owner · Zeo Energy Corp.

ZEO

Zeo Energy Corp.

Buy
Filing details

SEC transaction code P

Class A Common Stock · Indirect ownership · See Footnote · Reported balance after transaction: 920500 · SEC code covers open-market or private transactions · The price reported in Column 4 is a weighted average price of $0.2301. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. · Comprises shares of Class A Common Stock of the Issuer held of record by LCB Trust, for which the Reporting Person serves as trustee and may, therefore, be deemed to be the beneficial owner of shares held by such entity. The Reporting Person disclaims beneficial ownership over any such shares held by such entity.

2026-11-182026-11-20

≈ $24,840.45

107,955 shares/units

SEC 4Follow

Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.

Advertisement